Cargando…

Outcomes of older patients with diffuse large B-cell lymphoma treated with R-CHOP: 10-year follow-up of the LNH03-6B trial

The LNH03-6B trial was a phase 3 randomized trial evaluating the efficacy of first-line rituximab, cyclophosphamide, doxorubicine, vincristine and prednisone (R-CHOP) delivered every 2 weeks (R-CHOP14) or 3 weeks (R-CHOP21) in patients with diffuse large B-cell lymphoma (DLBCL) aged 60 to 80 years w...

Descripción completa

Detalles Bibliográficos
Autores principales:	Camus, Vincent, Belot, Aurélien, Oberic, Lucie, Sibon, David, Ghesquières, Hervé, Thieblemont, Catherine, Fruchart, Christophe, Casasnovas, Olivier, Michot, Jean-Marie, Molina, Thierry Jo, Bosly, André, Joubert, Clémentine, Haioun, Corinne, Nicolas-Virelizier, Emmanuelle, Feugier, Pierre, Fitoussi, Olivier, Delarue, Richard, Tilly, Hervé
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	The American Society of Hematology 2022
Materias:	Regular Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9772793/ https://www.ncbi.nlm.nih.gov/pubmed/35737565 http://dx.doi.org/10.1182/bloodadvances.2022007609

Ejemplares similares

Aggressive lymphomas with renal involvement: a study of 48 patients treated with the LNH-84 and LNH-87 regimens. Groupe d'Etude des Lymphomes de l'Adulte.
por: Morel, P., et al.
Publicado: (1994)

Ibrutinib Associated with Rituximab-Platinum Salt-Based Immunochemotherapy in B-Cell Lymphomas: Results of a Phase 1b-II Study of the LYSA Group
por: Bonnet, Christophe, et al.
Publicado: (2022)

Central nervous system relapse in patients over 80 years with diffuse large B‐cell lymphoma: an analysis of two LYSA studies
por: Cabannes‐Hamy, Aurélie, et al.
Publicado: (2018)

Deep-Learning Assessed Muscular Hypodensity Independently Predicts Mortality in DLBCL Patients Younger Than 60 Years
por: Jullien, Maxime, et al.
Publicado: (2021)

Lenalidomide maintenance for diffuse large B‐cell lymphoma patients responding to R‐CHOP: quality of life, dosing, and safety results from the randomised controlled REMARC study
por: Thieblemont, Catherine, et al.
Publicado: (2019)

Central nervous system relapse in younger patients with diffuse large B-cell lymphoma: a LYSA and GLA/DSHNHL analysis
por: Thieblemont, Catherine, et al.
Publicado: (2023)

P1079: VERY LONG-TERM FOLLOW-UP OF RITUXIMAB MAINTENANCE IN YOUNG PATIENTS WITH MANTLE CELL LYMPHOMA INCLUDED IN THE LYMA TRIAL, A LYSA STUDY.
por: Sarkozy, Clementine, et al.
Publicado: (2023)

P1217: INTRATHECAL METHOTREXATE PROPHYLAXIS AND CENTRAL NERVOUS SYSTEM RELAPSE IN PATIENTS WITH DIFFUSE LARGE B-CELL LYMPHOMA TREATED WITH INTENSIFIED R-ACVBP STRATEGY
por: Renaud, L., et al.
Publicado: (2022)

Fatigue level changes with time in long-term Hodgkin and non-Hodgkin lymphoma survivors: a joint EORTC-LYSA cross-sectional study
por: Busson, Raphaël, et al.
Publicado: (2019)

High-risk stage IIB Hodgkin lymphoma treated in the H10 and AHL2011 trials: total metabolic tumor volume is a useful risk factor to stratify patients at baseline
por: Rossi, Cédric, et al.
Publicado: (2022)

Importancia del antígeno CA125 como indice pronostico para el linfoma no Hodgkin (LNH)
por: Rivera Vázquez, Maribel Teresa
Publicado: (2005)

Association of reduced relative dose intensity and survival in lymphoma patients receiving CHOP-21 chemotherapy
por: Pettengell, R., et al.
Publicado: (2008)

P1186: A LARGE FRENCH REAL WORLD MULTICENTRIC PROSPECTIVE COHORT OF PATIENTS WITH LYMPHOMA (REALYSA STUDY): DESCRIPTION OF THE DIFFUSE LARGE B CELL LYMPHOMA PATIENTS IN REAL WORLD IN FRANCE
por: Ghesquieres, H., et al.
Publicado: (2022)

A French multicentric prospective prognostic cohort with epidemiological, clinical, biological and treatment information to improve knowledge on lymphoma patients: study protocol of the “REal world dAta in LYmphoma and survival in adults” (REALYSA) cohort
por: Ghesquières, Hervé, et al.
Publicado: (2021)

In Situ Hepatitis C NS3 Protein Detection Is Associated with High Grade Features in Hepatitis C-Associated B-Cell Non-Hodgkin Lymphomas
por: Canioni, Danielle, et al.
Publicado: (2016)

Deep Learning Approach to Automatize TMTV Calculations Regardless of Segmentation Methodology for Major FDG-Avid Lymphomas
por: Revailler, Wendy, et al.
Publicado: (2022)

Combining gene expression profiling and machine learning to diagnose B-cell non-Hodgkin lymphoma
por: Bobée, Victor, et al.
Publicado: (2020)

Tafasitamab for the treatment of relapsed or refractory diffuse large B-cell lymphoma
por: Salles, Gilles, et al.
Publicado: (2021)

S226: EFFICACY OF ANTI-PD1 THERAPY IN RELAPSED OR REFRACTORY EXTRANODAL NK/T CELL LYMPHOMA: A MATCHED COHORT ANALYSIS FROM THE LYSA
por: Marouf, Amira, et al.
Publicado: (2023)

S233: AXICABTAGENE CILOLEUCEL AS SECOND-LINE THERAPY FOR LARGE B-CELL LYMPHOMA IN TRANSPLANT-INELIGIBLE PATIENTS: FINAL ANALYSIS OF ALYCANTE, A PHASE 2 LYSA STUDY
por: Houot, Roch, et al.
Publicado: (2023)

Infradiaphragmatic Hodgkin lymphoma: a large series of patients staged with PET-CT
por: Rossi, Cédric, et al.
Publicado: (2017)

c‐MYC and p53 expression highlight starry‐sky pattern as a favourable prognostic feature in R‐CHOP‐treated diffuse large B‐cell lymphoma
por: Bouroumeau, Antonin, et al.
Publicado: (2021)

Positron emission tomography-imaging assessment for guiding strategy in patients with relapsed/refractory large B-cell lymphoma receiving CAR T cells
por: Galtier, Jean, et al.
Publicado: (2022)

Humoral immune depression following autologous stem cell transplantation is a marker of prolonged response duration in patients with mantle cell lymphoma
por: Bouard, Louise, et al.
Publicado: (2022)

Axicabtagene ciloleucel as second-line therapy in large B cell lymphoma ineligible for autologous stem cell transplantation: a phase 2 trial
por: Houot, Roch, et al.
Publicado: (2023)

Publisher Correction: Axicabtagene ciloleucel as second-line therapy in large B cell lymphoma ineligible for autologous stem cell transplantation: a phase 2 trial
por: Houot, Roch, et al.
Publicado: (2023)

Prolonged third complete remission after busulfan, thiotepa, and autologous stem cell transplant in a primary central nervous system lymphoma patient
por: Camus, Vincent, et al.
Publicado: (2018)

Deep-Learning (18)F-FDG Uptake Classification Enables Total Metabolic Tumor Volume Estimation in Diffuse Large B-Cell Lymphoma
por: Capobianco, Nicolò, et al.
Publicado: (2021)

Comparing the fermentation performance of Escherichia coli KO11, Saccharomyces cerevisiae 424A(LNH-ST) and Zymomonas mobilis AX101 for cellulosic ethanol production
por: Lau, Ming W, et al.
Publicado: (2010)

Clinical Response to CHOP vs. R-CHOP in Adult Patients with Diffuse Large B-Cell Lymphomas
por: Tariq, Ayesha, et al.
Publicado: (2018)

Nonrelapse mortality after CAR T-cell therapy for large B-cell lymphoma: a LYSA study from the DESCAR-T registry
por: Lemoine, Jean, et al.
Publicado: (2023)

Clinical Analysis of the HBV Infection Status of 135 Patients with Diffuse Large B Cell Lymphoma Treated with R-CHOP or CHOP/CHOP-Like Chemotherapy
por: Guo, Wei, et al.
Publicado: (2015)

Prognostic relevance of sarcopenia, geriatric, and nutritional assessments in older patients with diffuse large B-cell lymphoma: results of a multicentric prospective cohort study
por: Pénichoux, Juliette, et al.
Publicado: (2023)

A phase II study of the oral JAK1/JAK2 inhibitor ruxolitinib in advanced relapsed/refractory Hodgkin lymphoma
por: Van Den Neste, Eric, et al.
Publicado: (2018)

Molecular Characterization of Primary Mediastinal Large B-Cell Lymphomas
por: Donzel, Marie, et al.
Publicado: (2023)

Six-Year Results From RELEVANCE: Lenalidomide Plus Rituximab (R(2)) Versus Rituximab-Chemotherapy Followed by Rituximab Maintenance in Untreated Advanced Follicular Lymphoma
por: Morschhauser, Franck, et al.
Publicado: (2022)

Correlations between baseline (18)F-FDG PET tumour parameters and circulating DNA in diffuse large B cell lymphoma and Hodgkin lymphoma
por: Decazes, Pierre, et al.
Publicado: (2020)

Pembrolizumab in relapsed or refractory primary mediastinal large B-cell lymphoma: final analysis of KEYNOTE-170
por: Zinzani, Pier Luigi, et al.
Publicado: (2023)

Impact of relative dose intensity (RDI) in CHOP combined with rituximab (R-CHOP) on survival in diffuse large B-cell lymphoma
por: Terada, Yoshiki, et al.
Publicado: (2009)

Superior Mesenteric Artery Pseudoaneurysm Induced by Accidental Ingestion of a Foreign Body: Case Report
por: Al Harthy, Ahmed, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_sqenre4048v5t48s85bvel3rou